Bio Plus Co., Ltd (KOSDAQ: 099430)

Market Cap	292.80B
Revenue (ttm)	54.58B
Net Income (ttm)	20.01B
Shares Out	57.19M
EPS (ttm)	344.76
PE Ratio	14.85
Forward PE	n/a
Dividend	70.00 (1.40%)
Ex-Dividend Date	n/a

Volume	275,082
Open	5,040.00
Previous Close	5,030.00
Day's Range	4,970.00 - 5,090.00
52-Week Range	4,250.00 - 8,320.00
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 14, 2024

About Bio Plus

Bio Plus Co., Ltd engages in the research and development, production, and sale of bio products in South Korea. It offers dermal fillers under the SkinPlus – Hyal, Bio+ Dew, HyalDew, DeneB Classic, Stilea, and 3-Senses brand names. The company also provides medical products, including InterBlock, an absorbable anti-adhesion barrier; Synofil, a synovial fluid replacement; and Blad-Care, a solution to temporarily improve cystitis symptoms. In addition, it offers mesotherapy products, such as skin rejuvenation products under the Kiara Reju name; S...

• Industry: Surgical and Medical Instruments and Apparatus
• Founded: 2003
• Employees: 86
• Stock Exchange: KOSDAQ
• Ticker Symbol: 099430

Financial Performance

In 2023, Bio Plus's revenue was 65.04 billion, an increase of 14.68% compared to the previous year's 56.72 billion. Earnings were 25.58 billion, an increase of 21.02%.